D
Demeter Bio-Tech
ProvideS solutions based on microalgae technology for the sustainable development of society
About Demeter Bio-Tech
Demeter Biotechnology, operating under the brand name DMT Biotech, specializes in the large-scale production and commercialization of microalgae-based products. Utilizing a proprietary photon carbon smart biomanufacturing platform, the company employs synthetic biology to create specialized algal species. These species are then cultivated using a biological manufacturing system enhanced by artificial intelligence technology.
Read full description
Demeter's core products include fucoxanthin, EPA (eicosapentaenoic acid), and alternative proteins derived from microalgae. The company aims to capture more than 40% of the global market share in these segments.
Demeter serves a diverse range of clients, including those in the nutraceutical, pharmaceutical, and food industries, who seek sustainable and innovative raw materials. The company operates within the biotechnology and sustainable development markets, focusing on providing eco-friendly solutions.
Demeter's business model revolves around the mass production and sale of high-value microalgae-based raw materials. Revenue is generated through direct sales to industrial clients and partnerships with companies seeking sustainable alternatives to traditional raw materials.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- China
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 24.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Aug 2022 | $14M | $55M | HSG · Envision Energy | ↗ |
| SPINOUT✓Other financing | Jan 2019 | $0 | — | Chinese Academy Of Sciences | — |
Growth signals
Latest recorded traffic for Demeter Bio-Tech is 90 monthly website visits, down 43.8% over the last three months. Demeter Bio-Tech's team declined 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
HSG
Envision Energy
Other known investors1 additional known investor
Chinese Academy Of Sciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Demeter Bio-Tech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Demeter Bio-Tech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.